Literature DB >> 27767099

Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany.

Josef Rüschoff1, Annette Lebeau2, Hans Kreipe3, Peter Sinn4, Claus Dieter Gerharz5, Winfried Koch6, Stefanie Morris7, Johannes Ammann7, Michael Untch8.   

Abstract

Despite >10 years of routine human epidermal growth factor receptor 2 (HER2) testing in breast cancer, testing quality is still an issue. Guidelines recommend assessing HER2 positivity rates as a quality indicator; however, the extent to which patient- or tumor-related factors influence HER2 positivity is still unknown. The present study analyzed these influences to identify pathology centers with HER2 positivity rates unexplained by patient- or tumor-related factors. This observational, prospective study monitored routine HER2 testing at 57 institutes of pathology in Germany (January 2013-August 2014). Data collected included HER2 test result, patient- and tumor-related factors, sample source, and method of sample retrieval. Factors influencing HER2 positivity rates were identified by multiple logistic regression. Individual center effects were assessed in an extended multiple logistic regression model by their statistical significance after adjusting for the combined effect of patient- or tumor-related covariates and multiple testing. Analyses included 15 332 invasive breast cancer samples. Histologic grade showed the strongest influence on HER2 positivity, followed by hormone receptor status, histologic subtype, age, and nodal status (all P<0.0001). The overall HER2 positivity rate across centers was 14.4% (range 7.1-27.3%). A statistically significant center effect on the HER2 positivity rate was identified for three centers (P<0.05), with a trend toward a center effect for a further three (P<0.2). This study, the first of its kind, highlights that assessing HER2 testing quality with HER2 positivity rates should include standardized assessment of patient- or tumor-related characteristics to identify centers with HER2 testing quality issues more effectively. As treatment options for HER2-positive breast cancer continue to evolve, identifying the right patients is key.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27767099     DOI: 10.1038/modpathol.2016.164

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  35 in total

1.  Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations.

Authors:  S Bianchi; S Caini; M Paglierani; C Saieva; V Vezzosi; G Baroni; A Simoni; D Palli
Journal:  Pathol Oncol Res       Date:  2014-11-04       Impact factor: 3.201

2.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

4.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

5.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

6.  Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.

Authors:  Michael F Press; Guido Sauter; Leslie Bernstein; Ivonne E Villalobos; Martina Mirlacher; Jian-Yuan Zhou; Rooba Wardeh; Yong-Tian Li; Roberta Guzman; Yanling Ma; Jane Sullivan-Halley; Angela Santiago; Jinha M Park; Alessandro Riva; Dennis J Slamon
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

7.  Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Edward H Romond; Jong-Hyeon Jeong; Priya Rastogi; Sandra M Swain; Charles E Geyer; Michael S Ewer; Vikas Rathi; Louis Fehrenbacher; Adam Brufsky; Catherine A Azar; Patrick J Flynn; John L Zapas; Jonathan Polikoff; Howard M Gross; David D Biggs; James N Atkins; Elizabeth Tan-Chiu; Ping Zheng; Greg Yothers; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

8.  Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies.

Authors:  Annette Lebeau; Andreas Turzynski; Susanne Braun; Wera Behrhof; Barbara Fleige; Wolfgang D Schmitt; Tobias J Grob; Lia Burkhardt; Dieter Hölzel; Christian Jackisch; Christoph Thomssen; Volkmar Müller; Michael Untch
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

9.  Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program.

Authors:  Michael Bilous; Adrienne L Morey; Jane E Armes; Richard Bell; Peter H Button; Margaret C Cummings; Stephen B Fox; Glenn D Francis; Brigid Waite; Glenda McCue; Wendy A Raymond; Peter D Robbins; Gelareh Farshid
Journal:  Breast Cancer Res Treat       Date:  2012-06-08       Impact factor: 4.872

10.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.

Authors:  F Cardoso; A Costa; L Norton; E Senkus; M Aapro; F André; C H Barrios; J Bergh; L Biganzoli; K L Blackwell; M J Cardoso; T Cufer; N El Saghir; L Fallowfield; D Fenech; P Francis; K Gelmon; S H Giordano; J Gligorov; A Goldhirsch; N Harbeck; N Houssami; C Hudis; B Kaufman; I Krop; S Kyriakides; U N Lin; M Mayer; S D Merjaver; E B Nordström; O Pagani; A Partridge; F Penault-Llorca; M J Piccart; H Rugo; G Sledge; C Thomssen; L Van't Veer; D Vorobiof; C Vrieling; N West; B Xu; E Winer
Journal:  Ann Oncol       Date:  2014-09-18       Impact factor: 32.976

View more
  7 in total

1.  Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.

Authors:  Kathleen Lambein; Mieke Van Bockstal; Lies Vandemaele; Rudy Van den Broecke; Veronique Cocquyt; Sofie Geenen; Hannelore Denys; Louis Libbrecht
Journal:  Virchows Arch       Date:  2017-05-31       Impact factor: 4.064

2.  Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks.

Authors:  Chieh-Yu Lin; Eugene E Carneal; Daphne Y Lichtensztajn; Scarlett L Gomez; Christina A Clarke; Kristin C Jensen; Allison W Kurian; Kimberly H Allison
Journal:  Am J Clin Pathol       Date:  2017-09-01       Impact factor: 5.400

3.  Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.

Authors:  Andreas H Scheel; Frédérique Penault-Llorca; Wedad Hanna; Gustavo Baretton; Peter Middel; Judith Burchhardt; Manfred Hofmann; Bharat Jasani; Josef Rüschoff
Journal:  Diagn Pathol       Date:  2018-03-12       Impact factor: 2.644

4.  First-in-human phase 0 study of 111In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging.

Authors:  K A Kurdziel; E Mena; Y McKinney; K Wong; S Adler; T Sissung; J Lee; S Lipkowitz; L Lindenberg; B Turkbey; S Kummar; D E Milenic; J H Doroshow; W D Figg; M J Merino; C H Paik; M W Brechbiel; P L Choyke
Journal:  J Transl Sci       Date:  2018-07-13

5.  p-STAT3 expression in breast cancer correlates negatively with tumor size and HER2 status.

Authors:  Yan Wang; Qian Wang; Chih-Hsin Tang; Hua-Dong Chen; Gui-Nv Hu; Jun-Kang Shao; Xiao-Fang Dong; Lu-Lu Jin; Chao-Qun Wang
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

6.  Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer.

Authors:  Lan Shu; Yiwei Tong; Zhuoxuan Li; Xiaosong Chen; Kunwei Shen
Journal:  Cancers (Basel)       Date:  2022-08-31       Impact factor: 6.575

7.  Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018.

Authors:  Lidija Stevanovic; Matthias Choschzick; Linda Moskovszky; Zsuzsanna Varga
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-18       Impact factor: 4.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.